Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States

Liver Transplantation

Volumn 24, Issue 6, 2018, Pages 735-743

  Kwong, Allison ^a   Kim, W Ray ^a   Mannalithara, Ajitha ^a   Heo, Nae Yun ^b   Udompap, Prowpanga ^a   Kim, Donghee ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; NONALCOHOLIC FATTY LIVER; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; UNITED STATES; CHRONIC HEPATITIS C; DISEASE EXACERBATION; DRUG EFFECT; END STAGE LIVER DISEASE; EPIDEMIOLOGY; HEPACIVIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; SUSTAINED VIROLOGIC RESPONSE; TRANSPLANTATION; VIROLOGY;

ANTIVIRAL AGENTS; COHORT STUDIES; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SUSTAINED VIROLOGIC RESPONSE; TISSUE AND ORGAN PROCUREMENT; UNITED STATES; WAITING LISTS;

EID: 85044413172     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24973     Document Type: Article

References (27)

1. Saxena V, Terrault N. Current management of hepatitis C virus: regimens for peri-liver transplant patients. Clin Liver Dis 2015;19:669-688.
2. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293-300.
3. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011;31:1090-1101.
4. Udompap P, Mannalithara A, Heo NY, Kim D, Kim WR. Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. J Hepatol 2016;64:1027-1032.
5. Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, et al. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl 2012;18:1471-1478.
6. Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, et al. OPTN/SRTR 2013 annual data report: liver. Am J Transplant 2015;15(suppl 2):1-28.
7. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
8. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132:1746-1756.
9. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008;15:699-709.
10. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al.; for SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-659.
11. Mathur AK, Ashby VB, Fuller DS, Zhang M, Merion RM, Leichtman A, Kalbfleisch J. Variation in access to the liver transplant waiting list in the United States. Transplantation 2014;98:94-99.
12. Vutien P, Hoang J, Brooks L Jr, Nguyen NH, Nguyen MH. Racial disparities in treatment rates for chronic Hepatitis C: analysis of a population-based cohort of 73,665 patients in the United States. Medicine (Baltimore) 2016;95:e3719.
13. Lu M, Li J, Rupp LB, Zhou Y, Holmberg SD, Moorman AC, et al. Changing trends in complications of chronic hepatitis C. Liver Int 2018;38:239-247.
14. Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, Volk ML. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol 2015;49:690-696.
15. Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, et al. OPTN/SRTR 2015 annual data report: liver. Am J Transplant 2017;17(suppl 1):174-251.
16. Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15:397-404.
17. Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015;62:79-86.
18. Bunchorntavakul C, Reddy KR. Management of hepatitis C before and after liver transplantation in the era of rapidly evolving therapeutic advances. J Clin Transl Hepatol 2014;2:124-133.
19. Bunchorntavakul C, Tanwandee T. Treatment of chronic hepatitis C in special populations. Gastroenterol Clin North Am 2015;44:883-900.
20. Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with impaired renal function. Liver Int 2016;36:807-816.
21. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al.; for SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685-697.
22. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al.; for Adefovir Dipovoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-1427.
23. Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 2016;65:692-699.
24. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al.; for ANRS CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142-156.
25. van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol 2016;65(suppl):S95-S108.
26. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, et al.; for European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 2016;65:524-531.
27. Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 2017;65:804-812.